Alsactide

Alsactide (INN) (brand name Synchrodyn 1-17 or simply Synchrodyn, former development code name Hoechst 433), also known as alisactide, is a synthetic peptide and analogue of adrenocorticotropic hormone (ACTH) which is used in Italy as a diagnostic agent in kidney function for adrenal insufficiency.[1][2][3] Like ACTH, alsactide is thought to act as a non-selective agonist of the melanocortin receptors, including the ACTH receptor (MC2R). However, it appears to show a different profile of receptor selectivity relative to ACTH, as it apparently demonstrated no evidence of inhibition of endogenous ACTH in Addison's disease patients.[4]

Alsactide
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.047.442
Chemical and physical data
FormulaC99H155N29O21S
Molar mass2119.54 g/mol g·mol−1
3D model (JSmol)
  (verify)

See also

References
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 34–. ISBN 978-1-4757-2085-3.
  2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 33–. ISBN 978-3-88763-075-1.
  3. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 12–. ISBN 978-94-011-4439-1.
  4. George Kontogeorgos (1 January 2004). Molecular Pathology of the Pituitary. Karger Medical and Scientific Publishers. pp. 66–. ISBN 978-3-8055-7740-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.